Research programme: respiratory virus therapeutics - Ansun Biopharma

Drug Profile

Research programme: respiratory virus therapeutics - Ansun Biopharma

Alternative Names: ANSX EV68; ANSX MP10; ANSX RV14; AXSXS68; Inviridin; NEX-PIN; NEX-VAC; Viracidin

Latest Information Update: 06 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma
  • Class Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Enterovirus infections; Metapneumovirus infections; Respiratory syncytial virus infections
  • Discontinued Influenza virus infections

Most Recent Events

  • 30 Jul 2016 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
  • 30 Jul 2016 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
  • 27 Jul 2015 Preclinical development is ongoing for metapneumovirus infections and enterovirus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top